Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
OVAS's Cash to Debt is ranked higher than
75% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. OVAS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OVAS' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6548
N/A
No Debt
Equity to Asset 0.93
OVAS's Equity to Asset is ranked higher than
89% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OVAS: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
OVAS' s Equity to Asset Range Over the Past 10 Years
Min: 0.93  Med: 0.95 Max: 0.96
Current: 0.93
0.93
0.96
Interest Coverage No Debt
OVAS's Interest Coverage is ranked higher than
50% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OVAS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OVAS' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 7.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -58373.33
OVAS's Operating margin (%) is ranked lower than
98% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. OVAS: -58373.33 )
Ranked among companies with meaningful Operating margin (%) only.
OVAS' s Operating margin (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -58373.33
Net-margin (%) -59590.00
OVAS's Net-margin (%) is ranked lower than
98% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. OVAS: -59590.00 )
Ranked among companies with meaningful Net-margin (%) only.
OVAS' s Net-margin (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -59590
ROE (%) -60.36
OVAS's ROE (%) is ranked lower than
68% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. OVAS: -60.36 )
Ranked among companies with meaningful ROE (%) only.
OVAS' s ROE (%) Range Over the Past 10 Years
Min: -102.08  Med: -95.33 Max: -80.21
Current: -60.36
-102.08
-80.21
ROA (%) -56.21
OVAS's ROA (%) is ranked lower than
73% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. OVAS: -56.21 )
Ranked among companies with meaningful ROA (%) only.
OVAS' s ROA (%) Range Over the Past 10 Years
Min: -87.56  Med: -72.29 Max: -72.25
Current: -56.21
-87.56
-72.25
ROC (Joel Greenblatt) (%) -1624.94
OVAS's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. OVAS: -1624.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OVAS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3579.1  Med: -3561.61 Max: -2257.26
Current: -1624.94
-3579.1
-2257.26
» OVAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OVAS Guru Trades in

Q4 2014

OVAS Guru Trades in Q4 2014

Jim Simons 47,300 sh (New)
» More
Q1 2015

OVAS Guru Trades in Q1 2015

Jim Simons Sold Out
» More
Q4 2015

OVAS Guru Trades in Q4 2015

Jim Simons 97,435 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with OVAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.04
OVAS's P/B is ranked higher than
85% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. OVAS: 1.04 )
Ranked among companies with meaningful P/B only.
OVAS' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 23.6
Current: 1.04
0
23.6
P/S 1151.41
OVAS's P/S is ranked lower than
99.99% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. OVAS: 1151.41 )
Ranked among companies with meaningful P/S only.
OVAS' s P/S Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 63250.8
Current: 1151.41
0
63250.8
Current Ratio 14.73
OVAS's Current Ratio is ranked higher than
86% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. OVAS: 14.73 )
Ranked among companies with meaningful Current Ratio only.
OVAS' s Current Ratio Range Over the Past 10 Years
Min: 6.08  Med: 16.96 Max: 30.5
Current: 14.73
6.08
30.5
Quick Ratio 14.73
OVAS's Quick Ratio is ranked higher than
86% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OVAS: 14.73 )
Ranked among companies with meaningful Quick Ratio only.
OVAS' s Quick Ratio Range Over the Past 10 Years
Min: 6.08  Med: 16.96 Max: 30.5
Current: 14.73
6.08
30.5
Days Payable 1.00
OVAS's Days Payable is ranked lower than
98% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. OVAS: 1.00 )
Ranked among companies with meaningful Days Payable only.
OVAS' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.09
OVAS's Price/Net Cash is ranked higher than
91% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: 5.54 vs. OVAS: 1.09 )
Ranked among companies with meaningful Price/Net Cash only.
OVAS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.76  Med: 3.88 Max: 21.26
Current: 1.09
1.76
21.26
Price/Net Current Asset Value 1.06
OVAS's Price/Net Current Asset Value is ranked higher than
92% of the 893 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. OVAS: 1.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OVAS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.72  Med: 3.81 Max: 20.66
Current: 1.06
1.72
20.66
Price/Tangible Book 1.01
OVAS's Price/Tangible Book is ranked higher than
90% of the 1047 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. OVAS: 1.01 )
Ranked among companies with meaningful Price/Tangible Book only.
OVAS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 3.65 Max: 19.23
Current: 1.01
1.62
19.23
Earnings Yield (Greenblatt) (%) -2130.16
OVAS's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. OVAS: -2130.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OVAS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7212.99  Med: 0.00 Max: 0
Current: -2130.16
-7212.99
0

More Statistics

Revenue(Mil) $0
EPS $ -2.76
Beta3.56
Short Percentage of Float38.56%
52-Week Range $4.53 - 55.69
Shares Outstanding(Mil)27.28

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 0 3 19 89
EPS($) -2.01 -1.83 -1.64 -0.58
EPS without NRI($) -2.01 -1.83 -1.64 -0.58

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:3OS.Germany,
OvaScience, Inc. was established in 2011 & is based in Cambridge, Massachusetts. The Company is a life science company developing proprietary products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells. The Company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011.
» More Articles for NAS:OVAS

Headlines

Articles On GuruFocus.com
Oppenheimer Weighs in on Biotech Stocks: Opko Health, OvaScience Inc May 13 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Analyst Remains Bullish While OvaScience Posts Losses in Q4 Report Mar 18 2015 
OvaScience’s Fertility Treatment Shows Promise Jan 20 2015 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 

More From Other Websites
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against OvaScience Inc.... Feb 12 2016
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against OvaScience,... Feb 10 2016
Robbins Arroyo LLP: OvaScience, Inc. (OVAS) Misled Shareholders According to a Recently Filed Class... Feb 08 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of... Feb 03 2016
OvaScience to Present at Leerink Global Healthcare Conference Feb 03 2016
INVESTOR ALERT: Lundin Law PC Announces an Ongoing Investigation of OvaScience, Inc. and Urges... Feb 02 2016
GPM Announces Investigation of OvaScience, Inc. Feb 02 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of... Jan 28 2016
SHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against OvaScience, Inc.... Jan 26 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of... Jan 26 2016
SHAREHOLDER NOTICE: Goldberg Law PC Announces an Ongoing Investigation of Claims against OvaScience,... Jan 25 2016
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against OvaScience, Inc. -... Jan 25 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of OvaScience, Inc.... Jan 25 2016
OvaScience downgraded by Oppenheimer Jan 25 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of... Jan 22 2016
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against OvaScience,... Jan 22 2016
INVESTOR ALERT: Investigation of OvaScience, Inc. Announced by Law Offices of Howard G. Smith Jan 22 2016
OvaScience Announces 2016 Corporate Goals for Its Core Fertility Treatments Jan 11 2016
OVASCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2016
​Michelle Dipp to step aside as OvaScience CEO in July Jan 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK